美女内射毛片在线看免费人动物 I 4438x在线观看 I 日美女的逼逼 I 午夜宅男在线 I snh48国产大片永久 I 成年人小视频 I 国产在线播放网址 I 日韩a级片免费观看 I 麻豆综合在线 I 国产精品泄火熟女 I 伊人综合久久 I 亚洲精品免费一区亚洲精品免费精品一区 I 国产清纯美女白浆在线播放 I 高清|国产|在线视频在线观看免费 I 久久天天躁狠狠躁夜夜av不卡 I 日韩成人无码毛片一区二区 I 国产精品久久影院 I 丰满的人妻hd高清日本 I 女厕偷窥一区二区三区 I 又粗又长又硬义又黄又爽 I 在线观看吴梦梦 I 国产精品日韩一区二区 I 国产福利第一视频在线播放 I 后入内射欧美99二区视频 I 上司人妻互换hd无码 I 韩国成年人网站 I 国内高清久久久久久 I 国产黄a三级三级三级看三级黑人 I 一区二区免费视频 I av福利免费 I 火箭视频在线观看精品 I 国产一区国产二区国产三区 I 国产经典 欧美精品 I 亚洲伦理在线精品 I 韩国理论在线视频

Cell Line Name：

KIF5B(E15)-RET(E12)-Short/BaF3

Host Cell:

Ba/F3

Application:

Anti-proliferation assay and PD assay

Freeze Medium:

90% FBS+10% DMSO

Complete Culture Medium:

RPMI-1640+10%FBS+1 ug/ml puromycin

Mycoplasma Status:

Negative

Chromosomal rearrangements involving the gene that encodes the RET tyrosine kinase are known oncogenic drivers in 1% to 2% of patients with non–small cell lung cancer (NSCLC). These RET rearrangements occur with characteristic partners, most commonly KIF5B, but also CCDC6, NCOA, TRIM33, CUX1, KIAA1217, FRMD4A, and KIAA1468. They are typically identified in young patients with adenocarcinoma histology and minimal smoking history. Therapeutic targeting of RET-fusion–driven NSCLCs has taken the form of treatment with broad-spectrum tyrosine kinase inhibitors with anti-RET activity, such as cabozantinib (Cabometyx; Cometriq), vandetanib (Caprelsa), lenvatinib (Lenvima), RXDX-105, and sunitinib (Sutent). Cabozantinib and vandetanib have been the most heavily studied multi-kinase inhibitors (MKIs), with response rates of 20% to 50% in largely pretreated patients with RET-rearranged NSCLC. Sunitinib has been used in fewer patients to date with initial results demonstrating a 22% response rate. RXDX-105 has exhibited uniquely impressive response rates (75%) in patients with non–KIF5B-RET-fusion NSCLC, compared with 0% response in patients with KIF5B-RET-fusion–positive NSCLC. BLU-667 has demonstrated an objective response rate of 50% in patients with RET-fusion positive NSCLC, and LOXO-292 reported a 74% ORR in patients with RET-fusion positive NSCLC. Notably, RXDX-105, BLU- 667, and LOXO-292 have all demonstrated some central nervous system activity in these early phase trials. Future directions of RET inhibition in patients with RET-rearranged NSCLC include additional clinical validation of the next generation RET-selective inhibitors RXDX-105, BLU-667, and LOXO-292 and comparing multikinase inhibitors with RET-selective inhibitors to determine the optimal sequencing of RET-targeted therapies.

1. WB of KIF5B-RET (K15, R12S)/BaF3

2. Sanger of KIF5B-RET (K15, R12S)/BaF3

3. Anti-proliferation assay

Figure 4. CTG Proliferation Assay of BaF3 KIF5B-Ret (s) Cells (C6).